| Page 917 | Kisaco Research
 

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck

Heide Marika Düvel

DMPK Expert, Targeted Protein Degraders
Merck
 

Merve Mutlu-Koch

Postdoctoral Scholar
Novartis

Merve Mutlu-Koch

Postdoctoral Scholar
Novartis

Merve Mutlu-Koch

Postdoctoral Scholar
Novartis
 

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute

Marcus Hartmann

Project Group Leader, Facility Head
Max Planck Institute
 

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS
 

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS

Ryoma Hara

Principal Scientist, Chemistry
FIMECS
 

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech
 

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech

Giovanni Spagnolli

Co-founder, Chief Technology Officer
Sibylla Biotech
 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph